SEC Form 4 · accession 0001638599-16-000620
ALBANY MOLECULAR RESEARCH INC · AMRI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven R Hagen
Officer — SVP Manufacturing & Pharmaceut
Period of report
Feb 4, 2016
Accepted (ET)
Feb 8, 2016 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001065087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2016 | A | 9,988 | $15.77 | D | 41,966 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $15.77 | Feb 4, 2016 | A | 22,889 | A | — | Feb 4, 2026 | Common Stock | 22,889 | 22,889 | D |
Explanation of responses
- F1Option that is exercisable as to 1/4th of the shares annually on the anniversary date of the grant for each of the next four years.